Praxis raises $110 million to target CNS disease with Phase II drugs

Nicole DeFeudis

Editor

Just two months after bursting onto the neuroscience scene, Praxis Precision Medicines has added $110 million in funding to pursue therapies for central nervous system …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Praxis raises $110 million to target CNS disease with Phase II drugs

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Prax­is rais­es $110 mil­lion to tar­get CNS dis­ease with Phase II drugs

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Praxis raises $110 million to target CNS disease with Phase II drugs